Jan 10, 2022 Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
Nov 5, 2021 Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Oct 13, 2021 Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)
Sep 29, 2021 Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
Sep 28, 2021 Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
